Segment Reporting and Foreign Operations (Tables)

12 Months Ended

Dec. 31, 2017

Segment Reporting [Abstract]

Revenue from External Customers by Products and Services

Listed below are the sales by business segment for the years ended December 31, 2017, 2016 and 2015 (in thousands):

	% Change	2017		% Change	2016*		% Change	2015
Cardiovascular
Stand-alone devices	44%	$	275,431	23%	$	191,148	8%	$	155,414
Custom kits and procedure trays	6%	126,114		2%	119,226		5%	116,368
Inflation devices	8%	79,875		1%	73,916		1%	73,373
Catheters	13%	127,747		17%	113,367		11%	96,833
Embolization devices	8%	49,532		2%	46,035		3%	45,025
CRM/EP	15%	41,914		8%	36,459		3%	33,902
Total	21%	700,613		11%	580,151		6%	520,915
Endoscopy
Endoscopy devices	15%	27,239		12%	23,687		18%	21,234
Total	21%	$	727,852	11%	$	603,838	6%	$	542,149

* Certain product categories for 2016 have been adjusted from prior disclosure to reflect changes in product classifications to be consistent with updates in the management of our product portfolios in 2017.

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas

Our long-lived assets by geographic area at December 31, 2017, 2016 and 2015, consisted of the following (in thousands):

	2017		2016		2015
United States	$	202,504	$	194,715	$	186,389
Ireland	45,671		47,337		48,896
Other foreign countries	44,645		34,521		32,493
Total	$	292,820	$	276,573	$	267,778

Schedule of Segment Reporting Information, by Segment

Total depreciation and amortization by business segment for the years ended December 31, 2017, 2016, and 2015 consisted of the following (in thousands):

	2017		2016		2015
Cardiovascular	$	52,700	$	42,806	$	36,474
Endoscopy	882		949		951
Total	$	53,582	$	43,755	$	37,425

Total capital expenditures for property and equipment by business segment for the years ended December 31, 2017, 2016 and 2015 consisted of the following (in thousands):

	2017		2016		2015
Cardiovascular	$	38,437	$	32,613	$	50,927
Endoscopy	186		224		32
Total	$	38,623	$	32,837	$	50,959

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the years ended December 31, 2017, 2016 and 2015, are as follows (in thousands):

	2017		2016			2015
Net Sales (1)
Cardiovascular	$	700,613	$	580,151		$	520,915
Endoscopy	27,239		23,687			21,234
Total net sales	727,852		603,838			542,149
Operating expenses
Cardiovascular	281,095		218,659			187,492
Endoscopy	12,089		11,490			10,746
Total operating expenses	293,184		230,149			198,238
Operating income (loss) (1)
Cardiovascular	24,819		30,053			34,052
Endoscopy	8,250		4,823			3,491
Total operating income	33,069		34,876			37,543
Total other expense - net	2,812		(9,490		)	(6,343		)
Income tax expense	8,358		5,265			7,398
Net income	$	27,523	$	20,121		$	23,802

(1) Sales and operating income have been adjusted from prior disclosure to reflect changes in product classifications between our operating segments, which were made to be consistent with updates in the management of our product portfolios in 2017.

Reconciliation of Assets from Segment to Consolidated

Total assets by business segment at December 31, 2017, 2016 and 2015, consisted of the following (in thousands):

	2017		2016		2015
Cardiovascular	$	1,103,806	$	932,927	$	767,952
Endoscopy	8,005		9,876		10,776
Total	$	1,111,811	$	942,803	$	778,728